Palvella Therapeutics has completed its NDA submission for QTORIN rapamycin, a treatment for microcystic lymphatic malformations, backed by strong Phase 3 clinical data. The FDA has begun a rolling review and awarded a third year of Orphan Product Development (OOPD) funding, reducing regulatory risks and eliminating the need for further efficacy studies. With a solid cash reserve of $250.6 million, Palvella is well-positioned to support manufacturing, regulatory processes, and a planned US commercial launch in the first half of 2027. The approval probability is raised to 90%, and the company's valuation for this indication is increased to $4 billion, supporting a Buy rating and a higher price target.
Palvella Therapeutics is the subject of this update. For readers following the health sector, here is Pluang's market snapshot as of Sep 29, 2026 22:11 WIB: Out of 100 priced US health stocks, 17 rose and 82 fell. Notable movers include WGS at USD 80.80 with a 1-day change of -5.97%, HRTX at USD 0.31 with +5.41%, and DNA at USD 10.88 with +3.97%.
Precision Optics Corporation reported a strong Q4 with record revenue of $8.8 million, a 42% increase year-over-year, surpassing analyst estimates of $7.1 million. The company also beat EPS expectations, posting -$0.01 versus the predicted -$0.06, si...
Analyst firm Craig-Hallum adjusted Boot Barn Holdings' price target to $224, an 84.91% increase from its recent stock price of $121.14, reflecting strong growth potential. The company aims to expand merchandise margins by 60 basis points in fiscal 20...
Inventiva announced improved financial results for the first half of 2026, reducing its net loss to €69.5 million from €175.9 million the previous year. The company completed the final patient visit in its Phase 3 NATiV3 trial for MASH, with topline ...
Jabil is set to report its Q4 earnings on September 30, 2026, with analysts expecting earnings per share around $4.07 and revenue near $9.71 billion, marking a 16.5% revenue increase year-over-year. The company is benefiting from robust growth in AI ...
Netflix shares rose 1.5% after Deutsche Bank upgraded the stock from Hold to Buy, citing recent price declines as a buying opportunity and stronger international trends. However, other analysts remain cautious, with Wells Fargo downgrading Netflix to...
